Attached files
| file | filename |
|---|---|
| 8-K - 8-K - Sorrento Tech, Inc. | d770065d8k.htm |
Exhibit 99.1
For Immediate Release
Press Release
Roka Bioscience Reports Second Quarter 2014 Financial Results
Warren, NJ – August 11, 2014 – (PR Newswire) — Roka Bioscience, Inc. (NASDAQ: ROKA), a molecular diagnostics company focused on providing advanced testing solutions for the detection of foodborne pathogens, today reported its financial results for the three and six months ended June 30, 2014.
Financial Highlights
| • | Revenue of $1.4 million in the quarter, 107% year-over-year growth |
| • | Revenue of $2.2 million in the six months, 137% year-over year growth |
| • | $60 million initial public offering completed in July 2014 |
Financial Results
Revenues for the quarter ended June 30, 2014 rose 107% to $1.4 million, from $671,000 in the same period in 2013. Revenues for the six months ended June 30, 2014 rose 137% to $2.2 million, from $937,000 in the same period in 2013. The increased revenue in the quarter and six months resulted from an increase in the number of Atlas® instruments placed with commercial customers and increased commercial utilization of the Atlas® instruments. As of June 30, 2014, the Company had 36 instruments placed with customers under commercial agreements, compared to 21 instruments as of June 30, 2013.
Total operating expenses for the second quarter were $8.4 million compared to $7.9 million for the same period in 2013. Total operating expenses for the six months ended June 30, 2014 were $16.6 million compared to $15.9 million for the same period in 2013.
Net loss for the second quarter was $7.4 million, or a loss of $(11.28) per share, compared with $7.9 million, or a loss of $(15.96) per share, for the same period in 2013. Net loss for the six months ended June 30, 2014 was $15.7 million, or a loss of $(24.88) per share, compared with $15.7 million, or a loss of $(34.10) per share, for the same period in 2013.
As of June 30, 2014, the Company had $26.0 million in cash, which did not include the proceeds received by the Company in connection with the IPO.
“Our strong revenue growth in the quarter results from the growing demand for our Atlas Detection assays,” said Paul Thomas, Roka Bioscience President and Chief Executive Officer. “With the completion of our IPO in July, we believe we are positioned for continued growth.”
Conference Call
Roka Bioscience will host a conference call today at 8:30 a.m. Eastern Time to discuss these results and answer questions. To listen to the conference call live, go to http://rokabio.investorroom.com/ or dial 1-877-870-4263 for domestic callers and 1-412-317-0790 for international callers. A replay of the call will be available commencing two hours after the completion of the call through August 18, 2014 by dialing 1-877-344-7529 domestic and 1-412-317-0088 international, passcode 10050698. An online archive of the conference call will also be available at http://rokabio.investorroom.com/.
About Roka Bioscience
Roka Bioscience is a molecular diagnostics company focused on developing and commercializing advanced testing solutions for the food safety testing market. Our Atlas Detection Assays incorporate our advanced molecular technologies and are performed on our “sample-in, result-out” Atlas System that automates all aspects of molecular diagnostic testing on a single, integrated platform. The Atlas System and Detection Assays are designed to provide our customers with accurate and rapid test results with reduced labor costs and improved laboratory efficiencies. For more information, visit http://rokabio.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act, as amended (the “Exchange Act”). These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. Any statements contained herein (including, without limitation, statements to the effect that we “believe”, “expect”, “anticipate”, “plan” and similar expressions) that are not statements of historical fact should be considered forward-looking statements and should be read in conjunction with the Condensed Financial Statements included in this press release and the discussion below. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties and other factors that could cause our actual results, levels of activity, performance or achievement to differ materially from those expressed or implied by these forward looking statements. There are a number of important factors that could cause actual results to differ materially from those indicated by such forward-looking statements. Such factors include those set forth in the company’s filings with the Securities and Exchange Commission. We expressly disclaim any obligation to update any forward-looking statements, except as may be required by law. Given these uncertainties, you should not place undue reliance on these forward-looking statements. These forward-looking statements represent our estimates and assumptions only as of the date of this press release and, except as required by law, we undertake no obligation to update or review publicly any forward-looking statements, whether as a result of new information, future events or otherwise after the date of this press release.
Investor Contact:
Roka Bioscience, Inc.
Steve Sobieski
Chief Financial Officer
(908) 605-4621
ssobieski@rokabio.com
Condensed Statements of Operations and Comprehensive Loss
(unaudited)
(in thousands, except share and per share data)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2014 | 2013 | 2014 | 2013 | |||||||||||||
| Revenue |
$ | 1,390 | $ | 671 | $ | 2,218 | 937 | |||||||||
| Operating expenses: |
||||||||||||||||
| Cost of revenue |
1,573 | 1,676 | 2,838 | 3,549 | ||||||||||||
| Research and development |
2,227 | 1,945 | 4,069 | 3,697 | ||||||||||||
| Selling, general and administrative |
4,548 | 4,275 | 9,596 | 8,533 | ||||||||||||
| Amortization of intangible assets |
42 | 42 | 84 | 84 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Total operating expenses |
8,390 | 7,938 | 16,587 | 15,863 | ||||||||||||
| Loss from operations |
(7,000 | ) | (7,267 | ) | (14,369 | ) | (14,926 | ) | ||||||||
| Other income (expense): |
||||||||||||||||
| Change in fair value of financial instruments |
41 | (594 | ) | (562 | ) | (575 | ) | |||||||||
| Interest income (expense), net |
(378 | ) | (80 | ) | (768 | ) | (154 | ) | ||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Loss before income taxes |
(7,337 | ) | (7,941 | ) | (15,699 | ) | (15,655 | ) | ||||||||
| Income tax provision (benefit) |
12 | 1 | 17 | 1 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net loss and comprehensive loss |
$ | (7,349 | ) | $ | (7,942 | ) | $ | (15,716 | ) | $ | (15,656 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| Net Loss per Common Share: |
||||||||||||||||
| Basic and diluted |
$ | (11.28 | ) | $ | (15.96 | ) | $ | (24.88 | ) | $ | (34.10 | ) | ||||
|
|
|
|
|
|
|
|
|
|||||||||
| Weighted average common shares outstanding used in computing net loss per common share: |
||||||||||||||||
| Basic and diluted |
651,598 | 486,184 | 631,620 | 453,768 | ||||||||||||
|
|
|
|
|
|
|
|
|
|||||||||
Condensed Balance Sheets
(unaudited)
(in thousands, except share and per share data)
| June 30, | December 31, | |||||||
| 2014 | 2013 | |||||||
| ASSETS |
||||||||
| Current Assets: |
||||||||
| Cash and cash equivalents |
$ | 26,013 | $ | 32,728 | ||||
| Trade accounts receivable, net of $0 allowance for doubtful accounts |
566 | 277 | ||||||
| Inventories |
4,706 | 3,879 | ||||||
| Deferred tax assets |
— | 3,135 | ||||||
| Prepaid expenses and other current assets |
3,819 | 2,437 | ||||||
|
|
|
|
|
|||||
| Total current assets |
35,104 | 42,456 | ||||||
| Property and equipment, net |
13,258 | 14,510 | ||||||
| Intangible assets, net |
1,260 | 1,344 | ||||||
| Goodwill |
360 | 360 | ||||||
| Other assets |
2,823 | 444 | ||||||
|
|
|
|
|
|||||
| Total assets |
$ | 52,805 | $ | 59,114 | ||||
|
|
|
|
|
|||||
| LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS’ DEFICIT |
||||||||
| Current Liabilities: |
||||||||
| Accounts payable |
$ | 882 | $ | 1,226 | ||||
| Short-term deferred payments |
521 | 339 | ||||||
| Notes payable, current |
9,800 | 4,919 | ||||||
| Accrued expenses |
5,487 | 2,381 | ||||||
|
|
|
|
|
|||||
| Total current liabilities |
16,690 | 8,865 | ||||||
|
|
|
|
|
|||||
| Deferred payments |
3,216 | 3,205 | ||||||
| Convertible preferred stock warrant liability |
1,142 | 212 | ||||||
| Deferred tax liabilities |
40 | 40 | ||||||
| Other long-term liabilities |
342 | 339 | ||||||
|
|
|
|
|
|||||
| Total liabilities |
21,430 | 12,661 | ||||||
| Convertible Preferred Stock |
127,698 | 127,797 | ||||||
| Stockholders’ Deficit: |
||||||||
| Total stockholders’ deficit |
(96,323 | ) | (81,344 | ) | ||||
|
|
|
|
|
|||||
| Total liabilities and stockholders’ deficit |
$ | 52,805 | $ | 59,114 | ||||
|
|
|
|
|
|||||